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Background: Colorectal cancer is an important public health problem in Spain. Over the last decade, several regions
have carried out screening programmes, but population participation rates remain below recommended European
goals. Reminders on electronic medical records have been identified as a low-cost and high-reach strategy to increase
participation. Further knowledge is needed about their effect in a population-based screening programme. The
main aim of this study is to evaluate the effectiveness of an electronic reminder to promote the participation in
a population-based colorectal cancer screening programme. Secondary aims are to learn population’s reasons
for refusing to take part in the screening programme and to find out the health professionals’ opinion about the
official programme implementation and on the new computerised tool.
Methods/Design: This is a parallel randomised trial with a cross-sectional second stage. Participants: all the invited
subjects to participate in the public colorectal cancer screening programme that includes men and women aged
between 50–69, allocated to the eleven primary care centres of the study and all their health professionals. The
randomisation unit will be the primary care physician. The intervention will consist of activating an electronic
reminder, in the patient’s electronic medical record, in order to promote colorectal cancer screening, during a
synchronous medical appointment, throughout the year that the intervention takes place. A comparison of the
screening rates will then take place, using the faecal occult blood test of the patients from the control and the
intervention groups. We will also take a questionnaire to know the opinions of the health professionals. The main
outcome is the screening status at the end of the study. Data will be analysed with an intention-to-treat approach.
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Discussion: We expect that the introduction of specific reminders in electronic medical records, as a tool to facilitate
and encourage direct referral by physicians and nurse practitioners to perform colorectal cancer screening will mean an
increase in participation of the target population. The introduction of this new software tool will have good acceptance
and increase compliance with recommendations from health professionals.
Trial registration: Clinical Trials.gov identifier NCT01877018Background
Epidemiology
In Spain, colorectal cancer (CRC) has the highest incident-
rate in both sexes [1], with more than 25,000 new cases
diagnosed annually. Approximately 90% of CRC diag-
noses occur after the age of 60 and the majority (70%)
are sporadic cases. The incidence of CRC in Spain has
increased from 6 cases/100,000 inhabitants per year in
1973 to 30.4 cases/100,000 inhabitants per year in 2008,
with epidemiological estimates of up to 33,000 cases in
2012 [1]. It is the second leading cause of cancer death in
both sexes, after lung cancer in men and breast cancer
in women. Mortality rates appear to be levelling off in
recent years, most likely due to the improved diagnosis
and treatment of this disease [2]. Spain has an average
ranking in terms of incidence and mortality compared
with other European countries with 5-year-survival rates
standing at 54.7% for colon cancer, and 50.2% for rectal
cancer [3] and it is estimated that in the next few years,
one in 20 men and one in 30 women will develop a CRC
before the age of 75 [4].Current status of CRC screening in Spain
CRC meets the requirements for the implementation
of a screening programme [5]: it has a known natural
history based on precursor lesions (adenomatous polyps),
represents a public health problem owing to its high inci-
dence and mortality rate, there are effective tests available
for the early detection of the illness and its treatment
in early stages improves its prognosis with tests widely
accepted by the public. The purpose of screening is to
reduce disease-specific mortality, with minimal risks of
over-diagnosis and over-treatment. The cost-effectiveness
of CRC screening programmes has been amply demon-
strated, where it is eight times more cost-effective than
screening for breast cancer in Spain. There is international
consensus on the interest in screening the average-risk
population, namely men and women aged 50 and upwards
[6-9]. The effectiveness of screening using the faecal occult
blood test (FOBT) has been widely demonstrated in
randomised clinical trials with a drop in both mortality
(15% to 33%), and incidence rates (20%) [10,11]. The
current immunological faecal occult blood test (iFOBT),
based on the detection of human haemoglobin through
specific antibodies, have been established as the techniqueof choice in different screening programmes implemented
in Europe and have replaced conventional methods such
as the guaiac method, based on pseudoperoxidase activity
of haemoglobin [12-14]. The Council of the European
Union recommends the FOBT in men and women aged
50 to 74, every two years [15]. The Spanish Ministry of
Health’s National Health System Cancer Strategy promoted
the implementation of screening programmes for men and
women between 50 and 69 currently covering 14% of the
target population, with the aim of reaching 50% by 2015
[16]. These screening programmes implemented in Spain
follow the criteria of the European Guidelines for quality
assurance in colorectal cancer screening [17] and are coor-
dinated through the network of cancer screening, allowing
common methodological approaches to be followed and
the availability of compatible information systems to facili-
tate evaluation and comparison of both the process and
the results [18]. The participation of the population in
these programmes represents a quality indicator referred
to in the European guidelines and is an important pillar
for ensuring its effectiveness. Experts consider a minimum
uptake of at least 45% is acceptable, but it is recommended
to aim for a rate of at least 65%. However, similar to other
countries, results from existing programmes in Spain show
that the participation of the population is not reaching the
recommended objectives, with varying levels of uptake rates
(17%–42%), with the exception of the Basque Country
(64.3%) [19-23]. It can be generally said that participation
has been highest where there is increased primary health
care involvement.Strategies to increase participation: electronic reminders
Certain randomised clinical trials support the effectiveness
of different interventions promoted by primary care to
increase participation in CRC screening, although dem-
onstrating differences in their impact and depending on
the economic coverage of the tests, screening basal rates,
target level and number of interventions [24]. Some of
these initiatives eat into resources both in terms of
personnel and time, making their reproducibility impracti-
cal in certain primary health offices which are becoming
increasingly overburdened. Several authors point to new
technological strategies to improve the coverage and evalu-
ation of CRC screening [25]. The introduction of specific
electronic reminders or alerts in electronic medical records
Guiriguet-Capdevila et al. BMC Cancer 2014, 14:232 Page 3 of 10
http://www.biomedcentral.com/1471-2407/14/232(EMR) has proven effective to increase the practice of
different preventive activities, including cancer prevention,
with increases of up to 12–14% [26,27]. This increase is
most noticeable in centres with greater levels of cohesion,
where they already have a computerised medical record
system of the population in place. Despite its broad scope
and low cost, electronic reminders still remain an under-
utilised tool in the healthcare sector [28]. The introduction
of reminders aimed at physicians for the promotion of
CRC screening with the FOBT remains a controversial
matter in terms of its effectiveness in revised literature
[29,30]. However, these studies have been carried out in
countries that offer a context that is different to ours with
regards to the type of programme (population-based/
opportunistic), test economic coverage (public/insured),
test type (FOBT/colonoscopy) and degree of implementa-
tion of computerised medical records in health centres,
to name a few. A study has been carried out on how
professionals have adhered to executing the electronic
reminders, identifying ways of making this easier, such
as limiting the number of reminders, integrating them
into the medical visit and facilitating follow-up technical
support. Strategies to address barriers identified such as
the allocation of responsibility among medical and nursing
staff, visibility of alerts or the existence of a feedback
mechanism on its use have also been proposed [31,32].
Involvement of primary health care in the CRC screening
programme in Catalonia
A population-based programme for the early detection
of colorectal cancer in Barcelona started in 2009 [33].
Patients receive a nominal mail issued centrally from the
programme’s offices, inviting them to participate. The
quantitative iFOBT screening test is used, which is per-
formed at home and is distributed at the community
pharmacy offices attached to the colorectal cancer screen-
ing programme (CRCSP). Participants registering a negative
result are invited to participate again in two years. Positive
cases are referred by telephone to a specific consultation
for evaluation with a colonoscopy. If the colonoscopy
comes back normal, the patient is invited to repeat the
iFOBT in ten years time. In the event of endoscopic
findings, the patients are referred for follow-up in primary
care in the case of adenoma, or specific consultations, the
CRC High Risk Clinic or the CRC unit, depending on the
pathology found. The primary care health professionals
are informed of the implementation of the circuit in
the population they are treating and the importance of
its promotion, in a specific session provided at each pri-
mary care centre (PCC). Certain sections of the different
Primary Care medical scientific societies have expressed
their disagreement with the current approach to CRC
screening programmes that do not directly involve the
primary care provider.The magnitude of CRC as a public health problem, the
less than ideal participation reflected in the different
programmes that have recently been implemented in
Spain, international evidence of the benefits that the
involvement of primary care professionals has for the
participation in screening programmes and the low
levels of literature available nationwide, has prompted
us to perform this study.
Objectives
The main objective is to evaluate the effectiveness of an
electronic alert in patients’ EMR to increase their partici-
pation in a population-based CRC screening programme
in Barcelona.
The secondary objectives are:
1. To discover the reasons for non-participation in a
population-based CRC screening programme
2. To find out the opinion of health professionals
about the electronic alert (Colo-alert)
3. To find out the opinion of health professionals about
the population-based CRC screening programme.
Methods/Design
Methodology
The COLO-ALERT study is a randomised clinical trial
comparing standard clinical practice (control group) in
relation to the activation of an electronic alert in EMR
(intervention group) of patients in primary care to pro-
mote and increase participation in a population-based
CRCSP. It also comprises a second cross-sectional and
observational stage.
Stage 1: COLO-ALERT a randomised clinical trial
Design: A parallel randomised clinical trial.
Setting: Eleven PCC, representing nine care teams, in
urban areas, from the Primary Care Services of Barcelona,
of the Catalan Health Institute.
Participants
People involved to participate in the CRCSP and their
respective primary care health professionals from the
centres to which they are assigned. Table 1 shows the
criteria for CRCSP inclusion and exclusion.
Inclusion criteria:
– For patients:
a) men and women aged between 50 and 69 invited toparticipate in the CRCSP
b) to be assigned with a primary care physician (PCP) atone of the study centres.
– For health care professionals: physicians or nurses
working at the study centres.
Table 1 Inclusion and exclusion criteria for the
programme for early detection of colorectal cancer in
Barcelona
Programme for early detection of colorectal cancer in Barcelona
Target population Men and women aged 50–69 included in
Catalonia’s Registro Central de Asegurados
Exclusion criteria Personal history of colorectal cancer
Suspicion symptoms of colorectal cancer: blood
in stools, change in bowel habits for more than
6 weeks, unexplained weight loss or fatigue or
persistent abdominal discomfort
Family history of colorectal cancer: 2 first-degree
relatives (parents, siblings or children) diagnosed
with colorectal cancer or one first -degree relative
diagnosed with colorectal cancer before the age of 60
Family history of familial adenomatous polyposis and
other polyposis syndromes, or Lynch syndrome
History of colorectal disease susceptible to specific
monitoring (ulcerative colitis, Crohn’s disease,
colorectal adenomas)
Terminal illness or serious illness or disability that
would contraindicate further study of colon
History of total colectomy
Death
Colorectal examinations performed in the last
5 years
Address error
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Recruitment of participants
Recruitment: Whenever the population centre, is invited
to participate at first round of CRCSP, from July 2011 to
May 2012, the heads of coordination and management
of the programme conduct a training session addressed
at all staff in the centre about CRC screening and the
established circuit. The previous minutes of this meeting
are reserved for the research team for the presentation
of the study, inviting centres to participate. If a centre
agrees to participate, all its health professionals and their
respective patients that may participate in the CRC
screening programme are included in the study. The
follow-up period will be one year.
Collection of data and information sources: The heads
of CRCSP are asked to provide a list of the personal
identification code of patients invited to participate in
the study setting at the beginning of the study. They
are then encrypted from the Catalan Health Institute’s
Primary Care Services Information System and the physi-
cians and nurses assigned in the participating centres
are identified. Randomisation and allocation of the study
groups is then performed. At the end of the study, CRCSP
will provide a list with the result of the participation of
patients. The patient information is obtained based on
the personal identification code, from the EMR, thedata provided by the Primary Care Services Information
System, and the data provided by the heads of CRCSP,
creating a unified database for the purpose of linking
the information.
Randomisation: The PCP is the unit of randomisation.
The allocation of the participating physicians to the con-
trol or intervention group is carried out, by the statistician
of the study, through a stratified random sampling by
centre, allocating 50% of the physicians to the control or
intervention group, respectively. The nurses are allocated
to the control or intervention group according to the
study group of the PCP that they share patients care with.
Patients are allocated to the control or intervention group
according of the study group of their PCP (Figure 1).
Blinding: Given the nature of the intervention, it is not
possible to carry out blinding of the health professionals
randomised to the intervention group, neihter of the stat-
istic responsible for the data analysis. However, given the
objectivity of the primary outcome, we do not believe
the result could be influenced by this fact. Patients are
unaware of study group that they have been assigned to
and they have no access to the EMR. In addition, the
CRCSP representative responsible for obtaining the data
on the primary outcome does not know what study group
the invited population was allocated to.Interventions and procedures
Control group: Includes all health professionals randomised
as a control group and their assigned patients that have
been invited by the CRCSP They are following the proce-
dures of the Barcelona CRCSP functional plan [33].
Intervention group: Includes all health professionals
randomised as the intervention group and their assigned
patients that have been invited by the CRCSP. They are
following the CRCSP functional plan described above
along with the activation of an electronic alert linked to
the subjects’ personal identification code. Intervention
consists of the introduction of an alert in the patients’
EMR, appearing as a specific icon, in the agenda of
patients with appointments for that day, identifying
those subjects who have been invited to participate in
the CRCSP (Figure 2). It is intended for physicians and
nurses, to promote CRC screening actively during a
synchronous medical visit with the patient, by means of
a structured brief recommendation to this effect. They
are also invited to complete the data collection sheet
designed for the study and also entered into the EMR.
Health professionals from the intervention group receive a
specific training session during which they are explained
the features of the electronic alert and how it works.
The alert is activated once the population belonging to
the centre joins the screening program. Once completed,
it is then deactivated, with a maximum period of one
Assessed for eligibility:
Patients N=57.020
Professionals N= 280 
Target population:
Patients N= 46.995
Professionals N= 280  
(148 PCP, 132 N)
Randomization unit: PCP  
Excluded (N=10.025)




























































Professionals = 128 (72 PCP, 56 N)
Patients = 24.595




CRCSP development and a  
reminder in the EMR 
STAGE 1: Randomised clinical trial 
(effectiveness of Colo-Alert in EMR and  population’s reasons for non-participation in CRCSP)
Figure 1 Flow chart of the COLO-ALERT Study. PCP: Primary care physician, N: Nurse, CRCSP: Colorectal cancer screening programme, EMR:
electronic medical record, BQ: baseline questionnaire, FQ: final questionnaire.
Guiriguet-Capdevila et al. BMC Cancer 2014, 14:232 Page 5 of 10
http://www.biomedcentral.com/1471-2407/14/232month to refine it. In any other case, it remains visible
at each patient’s visit, until the end of the study (1 year).
Outcomes
Primary outcome
 CRC screening status (provived by CRCSP)
– Participation: performance of the iFOBT, by
invitation from CRCSP during the study period
(1 year).
– Non-participation: where the iFOBT is not
performed, by invitation from CRCSP during the
study period.
– Exclusion: detection of any exclusion criteria
through the CRCSP screening process.Secondary outcomes
Patient profiles: Data obtained from the EMR at the be-
ginning of the study.
Personal identification code, age, sex, socio-economic
deprivation index [34], body mass index, smoking (non-
smoker, smoker, ex-smoker), alcohol consumption (non-
drinker, low risk, high risk), clinical risk group (1:
healthy, 2: acute illness, 3: minor chronic illness, 4:
multiple minor chronic illness, 5: Dominant chronic
illness; 6: two dominant chronic illnesses 7: three dom-
inant chronic illnesses; 8: neoplasms; 9: catastrophic
illness), frequency (number of visits to the PCC during
the study period).
Related to the execution of the electronic alert (specific
data collection sheet in the EMR):
Figure 2 Study electronic alert. Specific icon (red dot) in front of the patient’s name on the list of appointments scheduled for the day.
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sheet included in the patients EMR by the health profes-
sionals) and date. Includes variables: oral informed consent,
participation in the screening programme using the iFOBT
undertaken prior to the physician’s medical appointment
at the PCC, reasons for non-participation, presence of
exclusion criteria specific to the screening program, inten-
tion to participate in the program.
Related to the screening result: Date and result of per-
formance of iFOBT provided by CRCSP at the end of
the study.
Sample size: The assigned population at the study cen-
tres aged between 50 and 69 is comprised of about 60,000
inhabitants. An estimated 90% of subjects will be invited
to participate in the CRCSP. In the event of a low screen-
ing uptake rate (30%), accepting an alpha risk of 0.05
and a beta risk less than 0.05 in a bilateral contrast,
19,181 patients are needed in each group to detect a
difference of 1.7 percentage points between the control
group and the intervention group.
Stage 2: cross-sectional COLO-ALERT
Design: Descriptive cross-sectional study.
Setting: The PCC included in stage 1.
Participants: All health professionals (physicians and
nurses) from a PCC who have given their consent to
participate.
Data collection: For the second cross-sectional stage
of the project, information on health professionals willbe collected based on two self-administered on-line ques-
tionnaires. An e-mail will be sent to the professional’s
work e-mail address, facilitated by the administration
of each centre, with a link to complete the survey and
personal access codes. A reminder will be sent to the
professionals who have not completed the form one week
later. The baseline questionnaire will be sent at the begin-
ning of the study, collecting data on the profile of the
professionals. The final questionnaire will be sent at
the end, in order for the professionals to evaluate the
CRCSP and the newly-introduced software tool.
Variables
Baseline questionnaire
Age, sex, profession and specialty, year of graduation, aver-
age work load, PCC, knowledge about colorectal cancer
screening (questions based on the general recommendations
of the National Clinical Practice Guideline will be included
on: epidemiology, risk stratification, effectiveness, testing,
target population, endoscopic surveillance intervals) [8].
Final questionnaire
The information will be categorised in nominal or nu-
meric variables, using a Likert scale, which includes the
following areas:
– Official program: Information received, process
operation, involvement of primary care professional,
recommendations for improvement (open).
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recommendations for improvement (open).
Statistical analysis
Once the data has been filtered, a standard deviation,
median and univariate descriptive analysis will be carried
out for the quantitative variables with normal and me-
dian distribution and inter-quartile range for quantitative
variables with non-normal distribution and frequency
and percentage for qualitative variables. Analysis will be
carried out by intention-to-treat (screening), where any
patients who are lost at the end of the year that the
intervention takes place due to changes of address, insti-
tutionalisation, or death will be considered as absent
from the screening. The same analysis will be later car-
ried out exclusively on patients who have completed the
intervention, and the results of these two methods will
be compared at the end. The bivariate relationship between
final participation in the CRCSP and each of the variables
that define the profile of the patients will be evaluated
using the t-test to obtain the mean difference in the
case of a quantitative variable and categorical and with
the Chi-square test to compare proportions in the case
of two qualitative variables. The frequency and percentage
of patients screened per group will be calculated and
the two proportions compared using the Chi-square
test (main objective). A multiple logistic regression model
will be set, where the screening will have been completed
by the dependent variable and the group and other var-
iables that define the profile of patients as independent
variables. This will allow us to discover which patient
characteristics are associated with participation in the
screening program. Finally, the evaluation survey variables
will be described for the professionals using a univariate
descriptive analysis, as well as a bivariate analysis where
associations will be evaluated two by two between survey
variables and the variables that define the profile of the
professionals (secondary objective). All statistical tests will
be performed with a bilateral confidence level of 95%. The
collected data will be analysed with the Stata statistical
programme version 12.1.
Ethics and confidentiality
The researchers undertake to respect the rules of Good
Clinical Practice and the Guidelines of Good Practice in
Research of the Primary Care research institute (IDIAP)
Jordi Gol, the requirements of the Declaration of Helsinki
and the general ethical clauses, particularly those regard-
ing the right to privacy, anonymity and confidentiality.
This project has the approval of the Jordi Gol Primary
Care Research Institute’s Ethics and Clinical Research
committee (P10/31). As our objective is to evaluate the
real impact of intervention in standard clinical practice,
the health care professional participating in the study willbe informed personally of their participation in a research
project that involves the activation of reminder systems to
promote population screening for colorectal cancer. They
will then receive detailed information about the study in a
specific session at their health centre. The acceptance of a
primary care centre’s participation in the study is decided
on jointly by the team of family medicine and nursing pro-
fessionals and all of them are included for randomisation.
We do not request written informed consent from the
healthcare professional participating in the study nor a
minimum number of revised alerts, to avoid bias of highly
motivated professionals and in order to simulate the actual
conditions of standard clinical practice as much as
possible. Similar experiences are cited in the reviewed
literature on the subject [35]. The participating patients
will be informed verbally about the study and their oral
consent to participate will be recorded in an electronic
data collection sheet, which will be entered into their
medical record.
Discussion
Numerous organisational and cognitive factors influencing
inadequate coverage in the actual practice of mass screen-
ing for CRC. These factors are derived from both patients
and healthcare and administration professionals. The low
participation is partly due to a lack of awareness of both
the illness itself and the early detection programmes, but
also to the existence of barriers for the conduct and results
of the tests. It is essential to inform the population in
question about the magnitude of CRC, the importance
of early detection, the benefits and risks of participating
in this type of programme and the need to coordinate
and involve the different health professionals and institu-
tions that participate directly or indirectly in a screening
program.
Direct recommendation by the family physician has
been described as one of the strongest predictors for the
performance of CRC screening, while the non-involvement
of this level of care in the recommendations is one of
the main reasons for it not being carried out [36,37]. Data
published in our sector show that 89% of subjects would
accept CRC screening if their primary care physician or
nurse suggested it; a percentage that is very different from
the data presented in the current population programmes
[38]. On the other hand, most of the eligible population
in countries with a long history of CRC screening have
shown that they have never received such a recommen-
dation [39]. The reality of the primary care professional’s
offices with an overload of care, preventive and bureau-
cratic tasks influence the poor level of recommendation
for CRC screening in the target population attending the
clinic for other reasons.
There are clinical studies in place that support the
effectiveness of electronic reminders in clinical practice.
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of the performance of FOBT, despite a low rate of revision
for electronic alerts (30%) [29]. Sequist et al. found an
increase in screening rates in those patients who attended
the surgery on more than two occasions during the study
period, although the difference was not significant, in part
due to very high baseline screening rates already in exist-
ence and also owing to the fact that the colonoscopy was
the test of choice of physicians when recommending
screening, with an uptake rate of only 50% of patients
[40]. Nease and Sequist evaluate the acceptance and
integration of reminders into medical practice with a
good general level of acceptance. However, there are
certain limitations, such as the moderate suitability of
alerts activated in patients considered candidates for
screening, possibly generating a tendency to wilfully over-
look the reminders, or see them as an interference in the
course of medical visits owing to care overload.
The following are worth mentioning as possible limita-
tions of this study:
The selection of the CRCSP target population is based
on data from patients included in Catalonia’s Registro
Central de Asegurados (Registry of Users of the Catalan
Health-care System). The percentage of patients on this
register that are assigned to a PCC, and would therefore
be invited to participate in the programme when it starts
screening, but in actual practice reside at another address
or attend another centre, accounts for 19% of the study
population, much higher than the average of Catalonia,
which was 8.1% according to 2012 figures. Alerts cannot
be activated in the medical records of these subjects, as
they do not have a physician assigned to the centre that
will be participating in the screening program. This may
involve a certain level of selection bias, but there is no
reason to believe that this population attending a differ-
ent centre to the one they are assigned may have some
distinguishing feature in relation to the study groups
and in any case, the control and intervention groups
are distributed on a random basis.
While the intervention is directed at the population
receiving care, this represents the majority of the assigned
population as the duration of the intervention is one year.
In 2011, 69% of patients aged between 50 and 69 made at
least one visit to their centre involved in the study, where
the overall average in Catalonia stands at 71%.
Losses during follow-up: changes of address, institutio-
nalisation or death may occur during the course of the
study. Any of these scenarios will be considered as the
screening having not taken place.
External validity: This involves a study of urban popu-
lation, but since the use of EMR is used across the board
in primary care in Catalonia, no differences in the effect-
iveness of electronic reminders are forecast according to
the scope of work.Contamination between professionals: Since the unit
of randomisation is the physician, certain contamination
could occur between centre professionals. In order to
minimise this, a training session on the computerised
tool exclusively for professionals in the intervention
group is provided. The decision to randomise by medical
professional was made by significant socio-demographic
differences existing in the reference population of the
study centres and by the differences in basal participation
found in other centres already screened in the same field,
exceeding 10% on occasion.
The CRC screening programmes in Spain are popula-
tion-based, providing access to the target population, and
biennial iFOBT is the test that has been selected, which has
shown better levels of acceptance and participation among
the population. On the other hand, health professionals
from the PCC have a long history in the use of EMR, with
universal coverage of the population. In light of this, we are
considering the introduction of a specific reminder in the
primary care EMR of the target population for an early
detection programme for CRC. The healthcare professional
will provide the identification and recommendation dir-
ectly to the patient when he/she attends his/her health
professional for any other reason, resulting in increased
participation, and thus improving its cost-effectiveness
and quality indicators.
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